The role of inflammation in heart failure: new therapeutic approaches.

Hippokration Hospital 114 Vasilissis Sofias Ave. 115 28 Athens, Greece e-mail: drtousoulis@ hotmail.com

[1]  N. Brunetti,et al.  Statins in Heart Failure. , 2013, Current vascular pharmacology.

[2]  M. Dimopoulos,et al.  Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. , 2011, Atherosclerosis.

[3]  C. Tsioufis,et al.  Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering. , 2010, International journal of cardiology.

[4]  M. Dimopoulos,et al.  Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. , 2010, Atherosclerosis.

[5]  B. Greenberg,et al.  Circulating levels of soluble intercellular adhesion molecule-1 (sICAM-1) independently predict depressive symptom severity after 12 months in heart failure patients , 2010, Brain, Behavior, and Immunity.

[6]  O. Melander,et al.  Carotid Intima-Media Thickness, Systemic Inflammation, and Incidence of Heart Failure Hospitalizations , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[7]  A. Trikas,et al.  Depression and heart failure. , 2009, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[8]  C. Stefanadis,et al.  Antidepressive treatment as a modulator of inflammatory process in patients with heart failure: effects on proinflammatory cytokines and acute phase protein levels. , 2009, International journal of cardiology.

[9]  G. Wang,et al.  Divergent Tumor Necrosis Factor Receptor-Related Remodeling Responses in Heart Failure: Role of Nuclear Factor-&kgr;B and Inflammatory Activation , 2009, Circulation.

[10]  D. Levy,et al.  Resistin, adiponectin, and risk of heart failure the Framingham offspring study. , 2009, Journal of the American College of Cardiology.

[11]  G. Filippatos,et al.  Self‐assessment of health status is associated with inflammatory activation and predicts long‐term outcomes in chronic heart failure , 2009, European journal of heart failure.

[12]  G. Limongelli,et al.  Novel insights into the role of cardiotrophin-1 in cardiovascular diseases. , 2009, Journal of molecular and cellular cardiology.

[13]  Raj Kishore,et al.  IL-10 Inhibits Inflammation and Attenuates Left Ventricular Remodeling After Myocardial Infarction via Activation of STAT3 and Suppression of HuR , 2009, Circulation research.

[14]  K. Huber,et al.  Prognostic value of apoptosis markers in advanced heart failure patients. , 2008, European heart journal.

[15]  W. Koenig,et al.  Lipoprotein-Associated and Secretory Phospholipase A2 in Cardiovascular Disease: The Epidemiological Evidence , 2009, Cardiovascular Drugs and Therapy.

[16]  C. Stefanadis,et al.  Chronic systemic inflammation accompanies impaired ventricular diastolic function, detected by Doppler imaging, in patients with newly diagnosed systolic heart failure (Hellenic Heart Failure Study) , 2009, Heart and Vessels.

[17]  G. Keren,et al.  Usefulness of serum myeloperoxidase in prediction of mortality in patients with severe heart failure. , 2008, The Israel Medical Association journal : IMAJ.

[18]  W. Kosmala,et al.  Plasma levels of TNF-&agr;, IL-6, and IL-10 and their relationship with left ventricular diastolic function in patients with stable angina pectoris and preserved left ventricular systolic performance , 2008, Coronary artery disease.

[19]  I. Kubota,et al.  Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. , 2007, American heart journal.

[20]  Sun Wook Cho,et al.  Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study. , 2008, Atherosclerosis.

[21]  J. Herlitz,et al.  C‐reactive protein, interleukin‐6, secretory phospholipase A2 group IIA and intercellular adhesion molecule‐1 in the prediction of late outcome events after acute coronary syndromes , 2007, Journal of internal medicine.

[22]  M. Shin,et al.  Synergistic Proinflammatory Effects of the Antiviral Cytokine Interferon-&agr; and Toll-Like Receptor 4 Ligands in the Atherosclerotic Plaque , 2007, Circulation.

[23]  Michael D. Schneider,et al.  TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. , 2007, The Journal of clinical investigation.

[24]  C. Stefanadis,et al.  Assessing inflammatory status in cardiovascular disease , 2007, Heart.

[25]  D. Kremastinos.  Anaemia in chronic heart failure: is there a rationale to treat? , 2007, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[26]  S. Hazen,et al.  Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. , 2007, Journal of the American College of Cardiology.

[27]  I. Kubota,et al.  Serum resistin is associated with high risk in patients with congestive heart failure--a novel link between metabolic signals and heart failure. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[28]  C. Stefanadis,et al.  Statins in heart failure. Beyond the lipid lowering effect. , 2007, International journal of cardiology.

[29]  P. Box.  Lipoprotein-associated phospholipase A2 activity and risk of heart failure: The Rotterdam study , 2007 .

[30]  E. Chaikof,et al.  Pathogen-Sensing Plasmacytoid Dendritic Cells Stimulate Cytotoxic T-Cell Function in the Atherosclerotic Plaque Through Interferon-&agr; , 2006, Circulation.

[31]  K. Sunagawa,et al.  Blockade of NF-κB improves cardiac function and survival after myocardial infarction , 2006 .

[32]  S. Gerondakis,et al.  The FASEB Journal • FJ Express Full-Length Article Absence of NF-�B subunit p50 improves heart failure after myocardial infarction , 2022 .

[33]  R. Peters,et al.  C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. , 2006, Atherosclerosis.

[34]  S. Yaturu,et al.  Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes. , 2006, Cytokine.

[35]  Y. Sharabi,et al.  Circulating adiponectin concentrations in patients with congestive heart failure , 2006, Heart.

[36]  Sanjiv J. Shah,et al.  High-sensitivity C-reactive protein and parameters of left ventricular dysfunction. , 2006, Journal of cardiac failure.

[37]  R. Frye,et al.  TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque , 2006, The Journal of experimental medicine.

[38]  S. Gerondakis,et al.  Absence of NF-kappaB subunit p50 improves heart failure after myocardial infarction. , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  K. Sunagawa,et al.  Blockade of NF-kappaB improves cardiac function and survival after myocardial infarction. , 2006, American journal of physiology. Heart and circulatory physiology.

[40]  E. Topol,et al.  Myeloperoxidase-Generated Oxidants Modulate Left Ventricular Remodeling but Not Infarct Size After Myocardial Infarction , 2005, Circulation.

[41]  T. Pischon,et al.  Association of plasma resistin levels with coronary heart disease in women. , 2005, Obesity research.

[42]  V. Cameron,et al.  Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. , 2005, Cardiovascular research.

[43]  Jan Frystyk,et al.  Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure , 2005, Circulation.

[44]  Reiko Ohmori,et al.  Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. , 2005, Journal of the American College of Cardiology.

[45]  S. Kumar,et al.  Serum resistin is associated with C-reactive protein and LDL- cholesterol in type 2 diabetes and coronary artery disease in a Saudi population , 2005, Cardiovascular diabetology.

[46]  P. Binkley,et al.  Depressive symptoms and inflammation among heart failure patients. , 2005, American heart journal.

[47]  J. Higaki,et al.  Serum markers of angiogenesis and myocardial ultrasonic tissue characterization in patients with dilated cardiomyopathy , 2005, European journal of heart failure.

[48]  K. Dickstein,et al.  Soluble CD40 ligand in acute and chronic heart failure. , 2005, European heart journal.

[49]  Stanley L Hazen,et al.  ATVB in Focus Redox Mechanisms in Blood Vessels , 2005 .

[50]  P. Vardas,et al.  Anaemia and heart failure: is its correction a therapeutic target? The role of erythropoietin. , 2005, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[51]  J. Lakoumentas,et al.  Cholesterol levels and the benefit of statins in heart failure. , 2005, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[52]  C. Stefanadis,et al.  Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. , 2005, International journal of cardiology.

[53]  T. Katagiri,et al.  Time-course of changes in the levels of interleukin 6 in acutely decompensated heart failure. , 2005, International journal of cardiology.

[54]  G. Keren,et al.  The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. , 2005, Journal of the American College of Cardiology.

[55]  T. Ueland,et al.  Inflammatory and anti‐inflammatory cytokines in chronic heart failure: Potential therapeutic implications , 2005, Annals of medicine.

[56]  D. Mele,et al.  Tumor Necrosis Factor- (cid:1) Receptor 1 Is a Major Predictor of Mortality and New-Onset Heart Failure in Patients With Acute Myocardial Infarction The Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) Study , 2005 .

[57]  Anand Rohatgi,et al.  Resistin Is an Inflammatory Marker of Atherosclerosis in Humans , 2005, Circulation.

[58]  A. Hofman,et al.  Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke: The Rotterdam Study , 2005, Circulation.

[59]  M. Wichers,et al.  Cytokines and major depression , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[60]  C. Garlanda,et al.  Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. , 2005, Annual review of immunology.

[61]  A. Mendez,et al.  Usefulness of C-reactive protein as an independent predictor of death in patients with ischemic cardiomyopathy. , 2005, The American journal of cardiology.

[62]  J. Spertus,et al.  Usefulness of depression to predict time to combined end point of transplant or death for outpatients with advanced heart failure. , 2004, The American journal of cardiology.

[63]  K. Dickstein,et al.  Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. , 2004, Journal of the American College of Cardiology.

[64]  Stamatis Adamopoulos,et al.  Comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. , 2004, The American journal of cardiology.

[65]  Gianni Tognoni,et al.  Prognostic Significance of the Long Pentraxin PTX3 in Acute Myocardial Infarction , 2004, Circulation.

[66]  C. Meisinger,et al.  Lipoprotein-Associated Phospholipase A2 Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General Population: Results From the 14-Year Follow-Up of a Large Cohort From Southern Germany , 2004, Circulation.

[67]  J. Spertus,et al.  Depression and health status in patients with advanced heart failure: a prospective study in tertiary care. , 2004, Journal of cardiac failure.

[68]  Marlene Goormastic,et al.  Serum Myeloperoxidase Levels Independently Predict Endothelial Dysfunction in Humans , 2004, Circulation.

[69]  T. Ganz.  Hepcidin in iron metabolism , 2004, Current opinion in hematology.

[70]  W. Yin,et al.  Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. , 2004, American heart journal.

[71]  G. Christensen,et al.  Elevated Levels of Activin A in Heart Failure: Potential Role in Myocardial Remodeling , 2004, Circulation.

[72]  Heejung Bang,et al.  Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study , 2004, Circulation.

[73]  S. Anker,et al.  Anemia in chronic heart failure: pathogenetic mechanisms. , 2004, Journal of cardiac failure.

[74]  D. Mann,et al.  Targeted Overexpression of Noncleavable and Secreted Forms of Tumor Necrosis Factor Provokes Disparate Cardiac Phenotypes , 2004, Circulation.

[75]  H. Bang,et al.  Lipoprotein-Associated Phospholipase A 2 , High-Sensitivity C-Reactive Protein , and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities ( ARIC ) Study , 2004 .

[76]  S. Rubin,et al.  Inflammatory Markers and Onset of Cardiovascular Events: Results From the Health ABC Study , 2003, Circulation.

[77]  Barbara Bottazzi,et al.  Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity. , 2003, Vaccine.

[78]  A. Luchner,et al.  Ventricular cardiotrophin-1 activation precedes BNP in experimental heart failure , 2003, Peptides.

[79]  Richard T. Lee,et al.  Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. , 2003, Journal of molecular and cellular cardiology.

[80]  P. Palatini,et al.  C-reactive protein in acute myocardial infarction: association with heart failure. , 2003, American heart journal.

[81]  D. Levy,et al.  Inflammatory Markers and Risk of Heart Failure in Elderly Subjects Without Prior Myocardial Infarction: The Framingham Heart Study , 2003, Circulation.

[82]  Eric J. Topol,et al.  Myeloperoxidase and Plasminogen Activator Inhibitor 1 Play a Central Role in Ventricular Remodeling after Myocardial Infarction , 2003, The Journal of experimental medicine.

[83]  W. Levy,et al.  Cytokines in Depression and Heart Failure , 2003, Psychosomatic medicine.

[84]  NoriyukiOuchi,et al.  Reciprocal Association of C-Reactive Protein With Adiponectin in Blood Stream and Adipose Tissue , 2003 .

[85]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[86]  S. Anker,et al.  Cytokines, apoptosis and cachexia: the potential for TNF antagonism. , 2002, International journal of cardiology.

[87]  S. Anker,et al.  The syndrome of cardiac cachexia. , 2002, International journal of cardiology.

[88]  J. Alonso-Martínez,et al.  C‐reactive protein as a predictor of improvement and readmission in heart failure , 2002, European journal of heart failure.

[89]  Yuetsu Tanaka,et al.  Expression of tumor necrosis factor ligand superfamily costimulatory molecules CD27L, CD30L, OX40L and 4-1BBL in the heart of patients with acute myocarditis and dilated cardiomyopathy. , 2002, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[90]  S. Frøland,et al.  Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. , 2002, Cardiovascular research.

[91]  B. Bozkurt,et al.  New therapeutics for chronic heart failure. , 2002, Annual review of medicine.

[92]  A. Coats,et al.  Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. , 2002, Journal of the American College of Cardiology.

[93]  M. Yamaoka-Tojo,et al.  Circulating levels of interleukin 18 reflect etiologies of heart failure: Th1/Th2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure. , 2002, Journal of cardiac failure.

[94]  P. Iversen,et al.  Decreased hematopoiesis in bone marrow of mice with congestive heart failure. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[95]  W. Kübler,et al.  Do cytokines enable risk stratification to be improved in NYHA functional class III patients? Comparison with other potential predictors of prognosis. , 2002, European heart journal.

[96]  M. Kinoshita,et al.  Relationship between plasma levels of cardiac natriuretic peptides and soluble Fas: plasma soluble Fas as a prognostic predictor in patients with congestive heart failure. , 2001, Journal of cardiac failure.

[97]  K. Nakao,et al.  Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[98]  C M O'Connor,et al.  Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. , 2001, Archives of internal medicine.

[99]  M. Hedger,et al.  Evidence for activin A and follistatin involvement in the systemic inflammatory response , 2001, Molecular and Cellular Endocrinology.

[100]  Anita Deswal,et al.  Cytokines and Cytokine Receptors in Advanced Heart Failure: An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST) , 2001, Circulation.

[101]  D. Tousoulis,et al.  Increased plasma adhesion molecule levels in patients with heart failure who have ischemic heart disease and dilated cardiomyopathy. , 2001, American heart journal.

[102]  G. Lowe,et al.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.

[103]  S. Frøland,et al.  CXC-chemokines, a new group of cytokines in congestive heart failure--possible role of platelets and monocytes. , 2000, Cardiovascular research.

[104]  S. Yamaguchi,et al.  Anti-inflammatory cytokine profile in human heart failure: behavior of interleukin-10 in association with tumor necrosis factor-alpha. , 1999, Japanese circulation journal.

[105]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[106]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[107]  J. Kjekshus,et al.  Elevated circulating levels of C-C chemokines in patients with congestive heart failure. , 1998, Circulation.

[108]  H. Oral,et al.  Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. , 1997, Circulation research.

[109]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[110]  G. Tilz,et al.  Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis , 1995, European journal of haematology.

[111]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[112]  L. Old,et al.  Tumor necrosis factor (TNF). , 1985, Science.

[113]  H. F. Wood,et al.  A study of C-reactive protein in the serum of patients with congestive heart failure. , 1956, American heart journal.